These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 19826477)

  • 1. Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.
    Soh J; Okumura N; Lockwood WW; Yamamoto H; Shigematsu H; Zhang W; Chari R; Shames DS; Tang X; MacAulay C; Varella-Garcia M; Vooder T; Wistuba II; Lam S; Brekken R; Toyooka S; Minna JD; Lam WL; Gazdar AF
    PLoS One; 2009 Oct; 4(10):e7464. PubMed ID: 19826477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant allele specific imbalance in oncogenes with copy number alterations: Occurrence, mechanisms, and potential clinical implications.
    Yu CC; Qiu W; Juang CS; Mansukhani MM; Halmos B; Su GH
    Cancer Lett; 2017 Jan; 384():86-93. PubMed ID: 27725226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
    Gandhi J; Zhang J; Xie Y; Soh J; Shigematsu H; Zhang W; Yamamoto H; Peyton M; Girard L; Lockwood WW; Lam WL; Varella-Garcia M; Minna JD; Gazdar AF
    PLoS One; 2009; 4(2):e4576. PubMed ID: 19238210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
    Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
    J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS mutant allele-specific imbalance in lung adenocarcinoma.
    Chiosea SI; Sherer CK; Jelic T; Dacic S
    Mod Pathol; 2011 Dec; 24(12):1571-7. PubMed ID: 21743433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic activating mutations are associated with local copy gain.
    Modrek B; Ge L; Pandita A; Lin E; Mohan S; Yue P; Guerrero S; Lin WM; Pham T; Modrusan Z; Seshagiri S; Stern HM; Waring P; Garraway LA; Chant J; Stokoe D; Cavet G
    Mol Cancer Res; 2009 Aug; 7(8):1244-52. PubMed ID: 19671679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher dosage of the epidermal growth factor receptor mutant allele in lung adenocarcinoma correlates with younger age, stage IV at presentation, and poorer survival.
    Oakley GJ; Chiosea SI
    J Thorac Oncol; 2011 Aug; 6(8):1407-12. PubMed ID: 21587084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS mutant allele-specific imbalance is associated with worse prognosis in pancreatic cancer and progression to undifferentiated carcinoma of the pancreas.
    Krasinskas AM; Moser AJ; Saka B; Adsay NV; Chiosea SI
    Mod Pathol; 2013 Oct; 26(10):1346-54. PubMed ID: 23599154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival.
    Hartman DJ; Davison JM; Foxwell TJ; Nikiforova MN; Chiosea SI
    Int J Cancer; 2012 Oct; 131(8):1810-7. PubMed ID: 22290300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR mutant allelic-specific imbalance assessment in routine samples of non-small cell lung cancer.
    Malapelle U; Vatrano S; Russo S; Bellevicine C; de Luca C; Sgariglia R; Rocco D; de Pietro L; Riccardi F; Gobbini E; Righi L; Troncone G
    J Clin Pathol; 2015 Sep; 68(9):739-41. PubMed ID: 26047622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers.
    Nomura M; Shigematsu H; Li L; Suzuki M; Takahashi T; Estess P; Siegelman M; Feng Z; Kato H; Marchetti A; Shay JW; Spitz MR; Wistuba II; Minna JD; Gazdar AF
    PLoS Med; 2007 Apr; 4(4):e125. PubMed ID: 17455987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent copy number gains drive PKCι expression and PKCι-dependent oncogenic signaling in human cancers.
    Liu Y; Justilien V; Fields AP; Murray NR
    Adv Biol Regul; 2020 Dec; 78():100754. PubMed ID: 32992230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.
    Tabernero J; Lenz HJ; Siena S; Sobrero A; Falcone A; Ychou M; Humblet Y; Bouché O; Mineur L; Barone C; Adenis A; Yoshino T; Goldberg RM; Sargent DJ; Wagner A; Laurent D; Teufel M; Jeffers M; Grothey A; Van Cutsem E
    Lancet Oncol; 2015 Aug; 16(8):937-48. PubMed ID: 26184520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of heterozygosity of chromosome 12p does not correlate with KRAS mutation in non-small cell lung cancer.
    Uchiyama M; Usami N; Kondo M; Mori S; Ito M; Ito G; Yoshioka H; Imaizumi M; Ueda Y; Takahashi M; Minna JD; Shimokata K; Sekido Y
    Int J Cancer; 2003 Dec; 107(6):962-9. PubMed ID: 14601056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung adenocarcinomas with HER2-activating mutations are associated with distinct clinical features and HER2/EGFR copy number gains.
    Li C; Sun Y; Fang R; Han X; Luo X; Wang R; Pan Y; Hu H; Zhang Y; Pao W; Shen L; Ji H; Chen H
    J Thorac Oncol; 2012 Jan; 7(1):85-9. PubMed ID: 22071781
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Chung WJ; Daemen A; Cheng JH; Long JE; Cooper JE; Wang BE; Tran C; Singh M; Gnad F; Modrusan Z; Foreman O; Junttila MR
    Proc Natl Acad Sci U S A; 2017 Dec; 114(51):E10947-E10955. PubMed ID: 29203670
    [No Abstract]   [Full Text] [Related]  

  • 17. Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial.
    Normanno N; Rachiglio AM; Lambiase M; Martinelli E; Fenizia F; Esposito C; Roma C; Troiani T; Rizzi D; Tatangelo F; Botti G; Maiello E; Colucci G; Ciardiello F;
    Ann Oncol; 2015 Aug; 26(8):1710-4. PubMed ID: 25851630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?
    Velho S; Moutinho C; Cirnes L; Albuquerque C; Hamelin R; Schmitt F; Carneiro F; Oliveira C; Seruca R
    BMC Cancer; 2008 Sep; 8():255. PubMed ID: 18782444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The chromosome 3q26 OncCassette: A multigenic driver of human cancer.
    Fields AP; Justilien V; Murray NR
    Adv Biol Regul; 2016 Jan; 60():47-63. PubMed ID: 26754874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant Kras copy number defines metabolic reprogramming and therapeutic susceptibilities.
    Kerr EM; Gaude E; Turrell FK; Frezza C; Martins CP
    Nature; 2016 Mar; 531(7592):110-3. PubMed ID: 26909577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.